Cargando…

Management of Hypertension in Children with Cardiovascular Disease and Heart Failure

Although primary chronic hypertension (HTN) is increasingly common in adolescence, secondary forms of HTN are more common among children. Primary HTN is associated with being overweight and/or a positive family history of HTN. Carotid intima-media thickness, a known risk factor for atherosclerosis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rad, Elaheh Malakan, Assadi, Farahnak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990921/
https://www.ncbi.nlm.nih.gov/pubmed/24791185
_version_ 1782312350371545088
author Rad, Elaheh Malakan
Assadi, Farahnak
author_facet Rad, Elaheh Malakan
Assadi, Farahnak
author_sort Rad, Elaheh Malakan
collection PubMed
description Although primary chronic hypertension (HTN) is increasingly common in adolescence, secondary forms of HTN are more common among children. Primary HTN is associated with being overweight and/or a positive family history of HTN. Carotid intima-media thickness, a known risk factor for atherosclerosis is frequent in both adults and children with HTN and other associated cardiovascular (CV) risk factors including obesity, dyslipidemia, diabetes and chronic kidney disease. Left ventricular (LV) hypertrophy is also a common finding in children and adolescents with newly diagnosed HTN. Children with certain medical conditions such as congenital heart disease and Kawasaki disease can develop premature atherosclerosis heart disease that may lead to coronary heart disease and heart failure. Life-style interventions are recommended for all children with HTN, with pharmacologic therapy added for symptomatic children based on the presence of co-morbidities. As an example, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blocker and/or calcium channel blockers would be best for children with CV risk factors such as diabetes or renal disease, whereas an ACE inhibitor in combination with a beta-blocker and diuretics including spironolactone are recommended for patients with heart failure and reduced LV ejection fraction. This report will summarize new developments in the management of pediatric HTN complicated with CV disease and heart failure and will address the appropriate antihypertensive therapy that could potentially reduce the future burden of adult CV disease.
format Online
Article
Text
id pubmed-3990921
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39909212014-05-01 Management of Hypertension in Children with Cardiovascular Disease and Heart Failure Rad, Elaheh Malakan Assadi, Farahnak Int J Prev Med Review Article Although primary chronic hypertension (HTN) is increasingly common in adolescence, secondary forms of HTN are more common among children. Primary HTN is associated with being overweight and/or a positive family history of HTN. Carotid intima-media thickness, a known risk factor for atherosclerosis is frequent in both adults and children with HTN and other associated cardiovascular (CV) risk factors including obesity, dyslipidemia, diabetes and chronic kidney disease. Left ventricular (LV) hypertrophy is also a common finding in children and adolescents with newly diagnosed HTN. Children with certain medical conditions such as congenital heart disease and Kawasaki disease can develop premature atherosclerosis heart disease that may lead to coronary heart disease and heart failure. Life-style interventions are recommended for all children with HTN, with pharmacologic therapy added for symptomatic children based on the presence of co-morbidities. As an example, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blocker and/or calcium channel blockers would be best for children with CV risk factors such as diabetes or renal disease, whereas an ACE inhibitor in combination with a beta-blocker and diuretics including spironolactone are recommended for patients with heart failure and reduced LV ejection fraction. This report will summarize new developments in the management of pediatric HTN complicated with CV disease and heart failure and will address the appropriate antihypertensive therapy that could potentially reduce the future burden of adult CV disease. Medknow Publications & Media Pvt Ltd 2014-03 /pmc/articles/PMC3990921/ /pubmed/24791185 Text en Copyright: © International Journal of Preventive Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Rad, Elaheh Malakan
Assadi, Farahnak
Management of Hypertension in Children with Cardiovascular Disease and Heart Failure
title Management of Hypertension in Children with Cardiovascular Disease and Heart Failure
title_full Management of Hypertension in Children with Cardiovascular Disease and Heart Failure
title_fullStr Management of Hypertension in Children with Cardiovascular Disease and Heart Failure
title_full_unstemmed Management of Hypertension in Children with Cardiovascular Disease and Heart Failure
title_short Management of Hypertension in Children with Cardiovascular Disease and Heart Failure
title_sort management of hypertension in children with cardiovascular disease and heart failure
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990921/
https://www.ncbi.nlm.nih.gov/pubmed/24791185
work_keys_str_mv AT radelahehmalakan managementofhypertensioninchildrenwithcardiovasculardiseaseandheartfailure
AT assadifarahnak managementofhypertensioninchildrenwithcardiovasculardiseaseandheartfailure